The World Health Organization-certified PyongSu Pharma joint venture (J/V) took "drastic measures" to keep operating in North Korea in order to avoid falling afoul of recent United Nations sanctions, Managing Director Remy Lardinois has told NK News.
A creative but risky solution now means that PyongSu Pharma will reportedly be able to continue operations in the DPRK despite a UN-mandated 120-day window for joint ventures to cease operations there passing on January 10.
The World Health Organization-certified PyongSu Pharma joint venture (J/V) took "drastic measures" to keep operating in North Korea in order to avoid falling afoul of recent United Nations sanctions, Managing Director Remy Lardinois has told NK News.
A creative but risky solution now means that PyongSu Pharma will reportedly be able to continue operations in the DPRK despite a UN-mandated 120-day window for joint ventures to cease operations there passing on January 10.
Try unlimited access
Only $1 for four weeks
-
Unlimited access to all of NK News: reporting, investigations,
analysis
-
Year-one discount if you continue past $1 trial period
-
The NK News Daily Update, an email newsletter to keep you in
the loop
-
Searchable archive of all content, photo galleries, special columns
-
Contact NK News reporters with tips or requests for reporting
Get unlimited access to all NK News content, including original reporting,
investigations, and analyses by our team of DPRK experts.
Subscribe
now
All major cards accepted. No commitments – you can cancel any time.
SHARE
COPY LINK
X
MASTODON
